familial Mediterranean fever
Rare disease · 2026–2026
1decision
1medicine
1carried consumer input
7individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| canakinumab Treatment of paediatric colchicine-resistant or intolerant familial Mediterranean fever (FMF) patients who continue canakinumab treatment into adulthood,… | Mar 2026 | Recommended | 7 individuals Australasian Society of Clinical Immunology and Allergy · Juvenile Arthritis Foundation Australia |
Who spoke
Australasian Society of Clinical Immunology and Allergy · Juvenile Arthritis Foundation Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.